Amarin CEO discusses the promising future of heart drug Vascepa, emphasizing its safety and potential approval by year-end. AMRN, a biotech stock, is poised for growth as Vascepa continues to demonstrate positive outcomes for heart health. Investors should keep a close eye on Amarin Corporation plc (ADR) for potential upside.